GlassScriptPhysician profile
Alan D Neiberg
NPI 1710939806
$2,604.95
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,126 · 2021: $117 · 2022: $20.26 · 2023: $14.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $292.30 | 2019-2020 | |
| Amgen INC. | $289.06 | 2019-2021 | |
| Lilly USA, LLC | $229.09 | 2019-2021 | |
| Novo Nordisk INC | $202.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $198.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $184.31 | 2019-2023 | |
| Glaxosmithkline, LLC. | $178.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.65 | 2019-2020 | |
| Amarin Pharma, INC. | $103.85 | 2019-2020 | |
| Melinta Therapeutics, LLC | $103.28 | 2019 | |
| Astellas Pharma US INC | $92.10 | 2020-2021 | |
| Allergan, INC. | $77.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.12 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.78 | 2020 | |
| Jazz Pharmaceuticals INC. | $50.34 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $40.60 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $32.31 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $31.07 | 2019-2020 | |
| Phadia US INC. | $29.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $25.43 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.10 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.88 | 2019 | |
| Ucb, INC. | $15.13 | 2019 | |
| Gilead Sciences, INC. | $14.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.62 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.07 | 2021 | |
| Boston Scientific Corporation | $12.73 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.20 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.86 | 2020 | |
| Nabriva Therapeutics, Plc | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Neiberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.